Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 28, Issue 5, Pages 406-414Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2012.1404
Keywords
alpha-fetoprotein (AFP); glycoprotein96 (gp96); hepatocellular carcinoma (HCC); immunity; vaccine
Categories
Funding
- Scientific Research Program
- Shaanxi Provincial Education Department [2007JK233, 2010JK484]
- Ministry of Education of China [205002]
- National Natural Science Foundation of China [81172135]
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is one of the most common malignant gastroenterological cancers over the world. alpha-fetoprotein (AFP) is an oncofetal protein produced during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein vaccine, glycoprotein 96 (gp96)/AFP. Our results demonstrated that AFP and gp96 synergistically exhibited significant increase in AFP-specific CD8(+) T-cell responses and impressive cytotoxic antitumor effect against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that tumor vaccine by cross-linking tumor antigen and gp96 is a promising approach to cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available